Purpose: Current epidemiologic evidence on the association between antihypertensive drugs and keratinocyte carcinoma (KC) risk is inconsistent. We sought to quantify this association by meta-analysis of observational studies. 
the antihypertensive drugs, thiazide diuretics are considered as the most photosensitive drugs, which may exhibit photochemical activity by UV-induced dissociation of the chlorine substituent leading to free radical reactions with lipids, proteins, and DNA. 12 Moreover, these photosensitizers may have the potential to increase the risk of developing UVR-related KC. 13 Current findings regarding the risk of KC have been inconsistent across the classes of antihypertensive drugs. 14 Elevated risk of BCC associated with diuretic use has been observed especially in overweight and obese individuals. 15 More recently, several case-control studies found that long-term use of diuretics was associated with increased risk of SCC. 14, 16 However, one cohort study in Danish patients found no association between increased risk of KC and long-term daily use of diuretics. 17 In contrast, a reduced risk of KC has been associated with the use of both angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs). 18 Little is known about the association between beta-adrenergic blocking agents (β-blockers) or calcium channel blockers (CCBs) and KC risk. The inconsistent results might be due to the limited information from individual studies (eg, small sample size and short follow-up) or variation in geographic region.
We therefore examined whether the use of any of the following 5 major classes of antihypertensive drugs-ACE inhibitors, ARBs, β-blockers, CCBs, or diuretics-was associated with KC risk by metaanalysis of observational studies.
| METHODS
The study was performed in accordance with the Meta-analysis of Observational Studies in Epidemiology guidelines for reviews of observational studies. 19 
| Search strategy and study selection
We systematically searched PubMed, Embase, and Cochrane Central
Register of Controlled Trials (CENTRAL) from inception to August 12, 2016, to identify observational studies (cohort studies and case-control studies) evaluating the association between exposure to antihypertensive drugs and risk of KC. Combined terms were used to search these databases without any restriction (Data S1). We also manually checked the reference lists of relevant reviews and metaanalyses to identify additional studies. Two reviewers (H.T. and S.
F.) independently selected the studies according to the following criteria: (1) clearly defined the exposure to antihypertensive drugs;
(2) "no use of antihypertensive drug" as the reference; (3) reported the outcome of KC (including BCC or SCC); (4) reported the odds ratio (OR), risk ratio, and hazard ratio with corresponding 95% confidence intervals (CIs) or sufficient data to calculate; and (5) cohort studies or case-control studies. We excluded abstracts and unpublished studies because of lack of information about patient and study characteristics. For the same sample used in multiple reports, only the latest or longest follow-up study was included. In the case of any missing information, we contacted the original author for clarification.
| Data extraction and quality assessment
Two reviewers (H.T. and S.F.) independently extracted data and assessed the quality of each study. We collected the following information: study design, region of study, drug use and reference, characteristics of participants, selection criteria, exposure definition, adjusted covariates, and the adjusted estimates of KC. In addition, we assessed the quality of studies using the Newcastle-Ottawa quality-assessment scale (NOS) on the basis of the following 3 domains: selection, comparability, and exposure/outcome. 20 The total NOS score ranges from 0 to 9, with a higher score indicating greater quality. The studies with scores of 0 to 5, 6 to 7, and 8 to 9 were considered low, moderate, and high quality, respectively. Any disagreements were resolved by consensus or referral to a third reviewer (J.H.).
| Statistical analysis
Odds ratios with 95% CI were used to estimate the risk of KC associated with antihypertensive drugs. Considering heterogeneity across studies, a random-effects meta-analysis model was used to calculate the estimates separately for ACE inhibitors, ARBs, β-blockers, CCBs, and diuretics. The I 2 statistic was used to assess heterogeneity, with I 2 of <25%, ≥25% and <75%, and ≥75% indicating low, moderate, and high heterogeneity, respectively. 21 Subgroup analysis was used to assess the consistency of associations between each class of antihypertensive drug and risk of KC within certain prespecified subgroups:
type of design (cohort study vs case-control study), region of study (Europe vs the United States), study quality (high quality vs moderate quality), adjusted for sun or UVR exposure (yes vs no), and adjusted for smoking (yes vs no) if there were sufficient data (at least 6 studies included 22 ). We performed a cumulative meta-analysis to evaluate the development of evidence over time by adding one study at a time in the order of date of publication. A sensitivity analysis was performed to assess the robustness of our findings by removing one study at a time. In addition, publication bias was assessed using Begg's and Egger's tests. All statistical analyses were performed with STATA (version 14; Stata Corp, College Station, Texas). A P value <.05 was considered significant.
KEY POINTS
• Current epidemiological studies of the association between antihypertensive drugs and keratinocyte carcinoma (KC) risk offer inconsistent results.
• Use of diuretics might be associated with an increased risk of KC, while ACE inhibitors or ARBs might be associated with a decreased risk of KC in patients at high risk.
• Use of β-blockers and CCBs might be associated with an increased risk of BCC but not SCC.
• Further postmarketing surveillance studies are warranted to confirm our findings.
| RESULTS
Of 2430 unique citations retrieved from electronic databases, 9 studies met the eligibility criteria. [13] [14] [15] 17, 18, [23] [24] [25] [26] Additionally, the data of one conference abstract 27 were updated in 2017; thus, we included the latest study. 28 Finally, we included 10 observational studies, ie, 6 cohort studies 15, 17, 18, 25, 26, 28 and 4 case-control studies 13, 14, 23, 24 ( Figure 1 ). The basic characteristics of the included studies are presented in Table 1 . Studies were published between 2008 and 2017; 6
were performed in Europe and 4 in the United States. It should be noted that one study 25 was conducted among renal transplant recipients and another study 18 included veterans at high risk for BCC and SCC, which was defined as experiencing at least 2 BCCs and/or SCCs in the 5 years preceding the study period. Diuretics were analyzed in 9 studies, ACE inhibitors in 2, ARBs in 2, ACE inhibitors or ARBs as a category in 2, β-blockers in 3, and CCBs in 3. The included studies were of moderate or high quality, with 5 assessed as high quality (8 out of 9 using NOS), and the other 5 studies as medium quality (NOS score from 6 to 7) (Table S1 ).
| Use of diuretics and KC risk
Eight studies [13] [14] [15] 17, 18, 23, 26, 28 reported an association between diuretic use and risk of BCC. Meta-analysis of these studies showed that use of diuretics was significantly associated with an increased risk of BCC compared with nonuse (OR, 1.10; 95% CI, 1.01-1.20) (Figure 2A ).
There was significant heterogeneity among studies (I 2 = 82.2%). The results from subgroup analysis are presented in Table 2 . A significantly increased risk of BCC was observed in cohort studies (OR, 1.09; 95% CI, 1.04-1.13), in studies of moderate quality (OR, 1.47; 95% CI, 1.04-2.07), or in studies with (OR, 1.07; 95% CI, 1.01-1.12) or without (OR, 1.14; 95% CI, 1.02-1.29) adjusting for smoking status. Our cumulative meta-analysis showed that the cumulative OR became significant when the study published by Nardone et al 28 was added ( Figure 3A) . A sensitivity analysis excluding one study at a time indicated that our results are robust unless the study by Nardone et al 28 was excluded ( Figure S1A ). There was no evidence of publication bias based on Egger's test (P = .20) or Begg's test (P = .27).
Seven studies 13, 14, 17, 18, 23, 24, 28 provided estimates of the association between diuretics and SCC risk. Meta-analysis of these studies showed that use of diuretics was significantly associated with an increased risk of SCC compared with nonuse (OR, 1.40; 95% CI, 1.19-1.66) ( Figure 2B ). There was significant heterogeneity among studies (I 2 = 81.8%). Our subgroup analysis did not find a significantly increased risk of SCC in US populations, in studies adjusted for sun or UVR exposure, and in studies adjusted for smoking status (Table 2 ). Our cumulative meta-analysis showed that the cumulative OR when including the second study in 2008 became significant (OR, 1.19; 95% CI, 1.04-1.36) ( Figure 3B ). Since then, the cumulative OR remained significant and stable. In addition, a sensitivity analysis excluding one study at a time did not significantly affect the pooled estimates ( Figure S1B ). There was no evidence of publication bias based on Egger's test (P = .30) or Begg's test (P = .23).
| Use of ACE inhibitors or ARBs and KC risk
Two studies 14, 28 reported on the association between ACE inhibitors and risk of BCC or SCC ( Figure 2 ); one found a significantly increased risk. 28 However, when we conducted a pooled analysis of the data from these 2 studies, there was no significant association between Two studies 18, 25 provided data on the association between use of ACE inhibitors or ARBs as a category and risk of KC in renal transplant recipients or patients at high risk for KC ( Figure 2 ). Both studies found a lower risk of BCC and SCC among patients using ACE inhibitors or ARBs. 18, 25 Our meta-analysis showed that use of ACE inhibitors or
ARBs was significantly associated with a decreased risk of both BCC (OR, 0.53; 95% CI, 0.39-0.71) and SCC (OR, 0.58; 95% CI, 0.42-0.80)
as compared with nonuse ( Figure 2 ).
| Use of β-blockers and KC risk
Three studies 14, 18, 25 presented adjusted estimates of the association between use of β-blockers and risk of BCC or SCC (Figure 2 ). When  FIGURE 1 Flow chart of the identification of eligible studies we performed a pooled analysis of these 3 studies, we found that use of β-blockers was significantly associated with increased risk of BCC compared with nonuse (OR, 1.09; 95% CI, 1.04-1.15), while there was no significant association between use of β-blockers and risk of SCC (OR, 0.89; 95% CI, 0.69-1.16). We detected no heterogeneity across studies for BCC (I 2 = 0%) and only moderate heterogeneity for SCC (I 2 = 68.1%). 
| DISCUSSION
In this meta-analysis of 10 observational studies, we found that use of diuretics was significantly associated with increased risk of KC, with a 10% increased odds for BCC and 40% increased odds for SCC. However, there was significant heterogeneity among studies in the overall and subgroup analyses. There was no significant association between diuretics and risk of KC (including SCC) in studies that adjusted for sun or UVR exposure. Our cumulative meta-analysis indicated that the cumulative OR of the association between use of diuretics and risk of SCC and BCC first became significant in 2008 and in 2017, respectively. There was some evidence of a significantly increased risk of BCC among patients using β-blockers or CCBs. The use of ACE inhibitors or ARBs might be associated with a decreased risk of KC in renal transplant recipients or patients at high risk for KC. However, the results of our meta-analysis should be interpreted with caution because of significant heterogeneity and the limited number of studies included.
Our findings are in agreement with several previous studies suggesting increased risk of KC among users of diuretics. 14, 28 Moreover, the cumulative meta-analysis showed that the increased risk of SCC was evident from 2008 onwards, and the effect was robust and unlikely to be a chance finding. A recent matched cohort study performed in a large electronic medical records repository of the Northwestern Medicine Enterprise Data Warehouse found that use of thiazide diuretics was associated with increased OR for development of both BCC and SCC. 28 Similarly, a case-control study performed in northern Denmark found a significantly increased risk of SCC and a borderline increase in the risk of BCC among patients taking diuretics. 14 These findings raise the possibility that KC risk is elevated among users of diuretics, especially thiazide diuretics. In addition, we found a nonsignificantly increased risk of KC (especially SCC) in studies that adjusted for sun or UVR exposure. Our findings indicated that sun or UVR exposure might be a potentially confounding or modifying factor. Additionally, it is well recognized that UVR has an important role in the development of KC. Our findings may be explained by the fact that diuretics can act as cocarcinogens with UVR to promote KC development. 13 The photosensitizing reaction followed by sun or UVR exposure can exacerbate the risk of sunburn and photo-damage and ultimately increase the risk of KC among patients taking diuretics. 29 Appropriately avoiding the exposure to sun or UVR may reduce the risk of KC in patients exposed to diuretics. However, the results from prior studies varied for BCC and SCC. A multicenter hospital-based case-control study in European populations found that users of diuretics had increased risk of SCC, but not BCC. 23 Another population-based case-control study showed a significant association between use of diuretics and development of SCC, but not BCC. 13 In our meta-analysis, we also found a stronger association with SCC (OR, 1.40) than with BCC (OR, 1.10) among patients taking diuretics, and our cumulative meta-analysis indicated that the significantly increased risk of SCC has been observed since 2008, while the increased risk of BCC became evident starting only in 2017. Furthermore, the risk of BCC associated with diuretics was similar between studies without controlling for sun or UVR exposure and studies controlling for sun or UVR exposure. This suggested that sun or UVR exposure might not be a confounder for BCC association. The OR of are required to confirm our findings.
Our meta-analysis of 3 studies 14,18,25 found a significant association between increased risk of BCC and use of β-blockers or CCBs.
The underlying mechanism of action is unclear. Some specific drugs in the classes of β-blockers (eg, sotalol) or CCBs (eg, nifedipine) are considered photosensitizing agents 34 and therefore might increase KC development by acting as cocarcinogens with UVR. However, FIGURE 3 Cumulative meta-analysis of studies ordered by publication year for the association between use of diuretics and risk of (A) BCC and (B) SCC. The studies are added at one time according to year of publication, and the results are summarized as each new study is added. BCC, basal cell carcinoma; CI, confidence interval; SCC, squamous cell carcinoma there was no significant difference between CCBs and β-blockers in terms of SCC risk. In addition to the fact that only 3 studies were included, it should be noted that the significant association was largely driven by one study performed by Schmidt et al. 14 The KC risk associated with CCBs or β-blockers remains uncertain and therefore requires exploration in more well-conducted studies. 34 and one matched-cohort study found significantly increased risk of KC among patients taking these drugs. 28 Therefore, future studies are warranted to clarify the association between use of ACE inhibitors or ARBs and development of KC.
Our study has 2 strengths. First, we systematically searched electronic databases to include all relevant studies. It is important to note that this is the first meta-analysis to address the association between antihypertensive drugs and risk of KC. Second, to confirm the robustness of our findings, prespecified subgroup analysis and sensitivity analysis were performed if there were sufficient data. However, our meta-analysis also has several potential limitations. First, because there was a lack of information in the eligible studies about the common risk factors for KC, such as UVR exposure, ethnicity, and smoking status, we extracted the adjusted estimates for potential confounders (eg, UVR exposure) whenever available and further conducted a subgroup analysis to minimize bias. Second, one potential confounder, health-seeking behaviors, may lead to detection bias. Individuals under hypertension management may be more likely to seek medical advice and be subject to increased surveillance, increasing the likelihood of disease diagnosis. However, we did not detect an increased risk of KC across all classes of antihypertensive drugs, which suggested that the increased risk might not be entirely due to increased scrutiny.
Third, information about cumulative doses and cumulative durations was unavailable from the selected studies, preventing us from performing a further dose-response analysis. Fourth, there was some evidence of significant heterogeneity across studies. Although we explored possible sources of heterogeneity by performing several subgroup analyses, we could not completely exclude heterogeneity.
Additionally, the limited number of studies included made us unable to perform this analysis for β-blockers, ACE inhibitors, ARBs, or CCBs.
Finally, it should be noted that not all antihypertensive drugs are recognized as being photosensitizing, which would lead to the heterogeneity in our meta-analysis. Further study should focus on a specific drug.
In summary, this meta-analysis based on evidence from 10 observational studies indicated that use of diuretics may be associated with increased risk of KC, while the use of ACE inhibitors or ARBs might be associated with decreased risk in patients at high risk. In addition, there is the possibility of an association between use of β-blockers or CCBs and increased risk of BCC. Because our study was observational, these results should be interpreted with caution and are insufficient evidence to alter current clinical recommendations. Nevertheless, these data support continued investigation of the potential mechanisms underlying this relationship.
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